FAAH Modulator Structure Optimizes Efficacy and Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FAAH inhibitors face challenges in achieving potent FAAH modulation with suitable pharmaceutical properties, including side effects such as sedation, abnormal gait, and hypothermia, and have limited efficacy in specific therapeutic indications like pain management and metabolic disorders.
Innovation Solution
The compound 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide, along with its pharmaceutically acceptable salts, prodrugs, and metabolites, exhibits higher IC50 values for CYP2D6 inhibition and improved physiological function profiles compared to comparator compounds, demonstrating enhanced FAAH-modulating activity with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FAAH inhibitors are used to achieve potent FAAH modulation, then FAAH activity is inhibited, but side effects such as sedation, abnormal gait, and hypothermia occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of FAAH inhibitors through various substituents (R1-R6 groups) to optimize the balance between FAAH inhibition potency and side effect profile. Different substituent patterns change the pharmacological parameters to reduce sedation, gait abnormalities, and hypothermia while maintaining enzyme inhibition.
Solution Approach 2:
The invention uses local quality by introducing specific functional groups at different positions (R1-R6) of the core molecular structure. Each substituent position can be independently optimized to achieve desired local interactions with the FAAH enzyme while minimizing off-target effects that cause side effects.
2Reliability
If FAAH inhibitors are developed for specific therapeutic indications like pain management, then therapeutic efficacy is improved, but pharmaceutical properties and side effect profiles remain suboptimal
Solution Approach 1:
The patent optimizes pharmaceutical properties by systematically varying molecular parameters such as lipophilicity, molecular weight, and hydrogen bonding capacity through different substituent combinations. This enables improvement of oral bioavailability, metabolic stability, and dosing characteristics while maintaining pain management efficacy.
3Reliability
If existing FAAH inhibitors are used, then some therapeutic benefits are achieved, but drug interactions and adverse reactions are not minimized
Solution Approach 1:
The invention extracts and eliminates the harmful metabolic pathways by designing inhibitors that avoid cytochrome P450 enzyme interactions. The molecular structure is specifically engineered to bypass major metabolic routes that lead to adverse reactions and drug-drug interactions, while preserving the desired FAAH inhibition therapeutic effect.
Data Source
AI summary
4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is also disclosed.